Characteristics of 147 myeloma patients according to RSV status
. | RSV-positive . | RSV-negative . | P . |
|---|---|---|---|
| No. of patients | 56 | 91 | NA |
| Median age, y (range) | 57 (31-79) | 58 (31-82) | .380 |
| Male (%) | 37 (66) | 63 (69) | .690 |
| Autologous stem cell transplantation, no. of patients | 39 | 51 | NA |
| Nonmyeloablative chemotherapy, no. of patients | 17 | 40 | .003 |
| Before therapy | |||
| Positive chest x-rays, no. of patients (%)* | 4 (7) | 4 (4) | .480 |
| Renal failure (%) | 16 (29) | 23 (26) | .718 |
| Median dexamethasone, mg (range) | 1 030 (0-3 820) | 965 (0-10 585) | .913 |
| Median cycles of chemotherapy (range) | 3.28 (0-10) | 2.99 (0-16) | .241 |
| Pulmonary function tests | |||
| Median DLCO (range) | 110 (55-169) | 105 (25-174) | .265 |
| Median FEV1 (range) | 85 (40-122) | 88 (51-125) | .271 |
| Median FVC (range) | 86 (42-120) | 88 (52-122) | .351 |
| After therapy | |||
| Neutropenia, below 10 × 109/L | |||
| No. of patients | 53 | 70 | NA |
| Median days (range) | 7 (1-19) | 8 (2-24) | .388 |
| Lymphopenia, below 7 × 109/L | |||
| No. of patients | 54 | 80 | NA |
| Median days (range) | 25 (2-95) | 29 (1-197) | .221 |
| Mucositis | |||
| Grade I (%) | 5 (9) | 10 (11) | .802 |
| Grade II (%) | 12 (21) | 16 (18) | .238 |
| Grade III (%) | 9 (16) | 15 (16) | .507 |
| Grade IV (%) | 8 (14) | 5 (5) | .038 |
| All severe complications (%) | 14 (25) | 15 (17) | .295 |
| Hypoxemia (%) | 13 (23) | 9 (10) | .032 |
| Tracheobronchitis (%) | 6 (11) | 0 | .003 |
| Pneumonia (%) | 6 (11) | 9 (10) | .873 |
| Intubation (%) | 2 (4) | 2 (2) | .623 |
| Transfer to intensive care unit (%) | 5 (9) | 6 (7) | .603 |
| Death within 30 days of therapy (%) | 3 (5) | 2 (2) | .715 |
. | RSV-positive . | RSV-negative . | P . |
|---|---|---|---|
| No. of patients | 56 | 91 | NA |
| Median age, y (range) | 57 (31-79) | 58 (31-82) | .380 |
| Male (%) | 37 (66) | 63 (69) | .690 |
| Autologous stem cell transplantation, no. of patients | 39 | 51 | NA |
| Nonmyeloablative chemotherapy, no. of patients | 17 | 40 | .003 |
| Before therapy | |||
| Positive chest x-rays, no. of patients (%)* | 4 (7) | 4 (4) | .480 |
| Renal failure (%) | 16 (29) | 23 (26) | .718 |
| Median dexamethasone, mg (range) | 1 030 (0-3 820) | 965 (0-10 585) | .913 |
| Median cycles of chemotherapy (range) | 3.28 (0-10) | 2.99 (0-16) | .241 |
| Pulmonary function tests | |||
| Median DLCO (range) | 110 (55-169) | 105 (25-174) | .265 |
| Median FEV1 (range) | 85 (40-122) | 88 (51-125) | .271 |
| Median FVC (range) | 86 (42-120) | 88 (52-122) | .351 |
| After therapy | |||
| Neutropenia, below 10 × 109/L | |||
| No. of patients | 53 | 70 | NA |
| Median days (range) | 7 (1-19) | 8 (2-24) | .388 |
| Lymphopenia, below 7 × 109/L | |||
| No. of patients | 54 | 80 | NA |
| Median days (range) | 25 (2-95) | 29 (1-197) | .221 |
| Mucositis | |||
| Grade I (%) | 5 (9) | 10 (11) | .802 |
| Grade II (%) | 12 (21) | 16 (18) | .238 |
| Grade III (%) | 9 (16) | 15 (16) | .507 |
| Grade IV (%) | 8 (14) | 5 (5) | .038 |
| All severe complications (%) | 14 (25) | 15 (17) | .295 |
| Hypoxemia (%) | 13 (23) | 9 (10) | .032 |
| Tracheobronchitis (%) | 6 (11) | 0 | .003 |
| Pneumonia (%) | 6 (11) | 9 (10) | .873 |
| Intubation (%) | 2 (4) | 2 (2) | .623 |
| Transfer to intensive care unit (%) | 5 (9) | 6 (7) | .603 |
| Death within 30 days of therapy (%) | 3 (5) | 2 (2) | .715 |
Positive chest x-ray: presence of infiltrates. DLCO indicates carbon monoxide diffusing capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; and NA, not applicable.